Global Blood Therapeutics, Inc. (NASDAQ:GBT) headquartered in South San Francisco, will host a conference call for the investment community to discuss the 3Q20 financial results on 5th November 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.gbt.com
Earnings Expectation
Global Blood Therapeutics, Inc. is set to announce third quarter earning results on Thursday 5th November 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, GBT to report 3Q20 loss of $ 0.73 per share from revenue of $ 43.98 million. For the full year, analysts anticipate top line of $ 144.68 million, while looking forward to loss of $ 3.41 per share bottom line.
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
